Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
ADUS
$112.98+Infinity%1D
Analyst Views on ADUS
Wall Street analysts forecast ADUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADUS is 132.20 USD with a low forecast of 117.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ADUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADUS is 132.20 USD with a low forecast of 117.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 113.490
Low
117.00
Averages
132.20
High
145.00
Current: 113.490
Low
117.00
Averages
132.20
High
145.00
BMO Capital
Market Perform
initiated
$120
2025-11-12
Reason
BMO Capital
Price Target
$120
2025-11-12
initiated
Market Perform
Reason
BMO Capital initiated coverage of Addus HomeCare with a Market Perform rating and $120 price target. The firm says it will look to get more constructive on the shares when concerns around Medicaid funding cuts start to ease. It remains positive on the longer-term macro shift toward in-home care, and Addus HomeCare's positioning.
RBC Capital
Outperform
maintain
$134 -> $139
2025-11-07
Reason
RBC Capital
Price Target
$134 -> $139
2025-11-07
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Addus HomeCare to $139 from $134 and keeps an Outperform rating on the shares. The company reported solid Q3 results, driven by strong 6.6% organic growth in Personal Care and should be well positioned to capitalize on additional M&A opportunities, the analyst tells investors in a research note.
TD Cowen
Buy
maintain
$139 -> $140
2025-11-05
Reason
TD Cowen
Price Target
$139 -> $140
2025-11-05
maintain
Buy
Reason
TD Cowen raised the firm's price target on Addus HomeCare to $140 from $139 and keeps a Buy rating on the shares. The firm updated its model following Q3 results.
Barclays
Andrew Mok
Underweight
maintain
$111 -> $117
2025-11-04
Reason
Barclays
Andrew Mok
Price Target
$111 -> $117
2025-11-04
maintain
Underweight
Reason
Barclays analyst Andrew Mok raised the firm's price target on Addus HomeCare to $117 from $111 and keeps an Underweight rating on the shares following the Q3 report. The firm says that despite a 2% revenue beat, Addus' adjusted EBITDA finished only 1.6% ahead of Street estimates driven by higher cost of services.
About ADUS
Addus HomeCare Corporation is engaged in providing home care services. Its segments include Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, to persons who are at increased risk of hospitalization or institutionalization, such as the elderly, chronically ill or disabled. The services it provides include assistance with bathing, grooming, feeding and dressing, medication reminders and others. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and related services for their families. The Hospice services it provides include palliative nursing care, social work, spiritual counseling, homemaker services and bereavement counseling. Its Home Health segment provides services that are medical in nature to individuals who may require assistance during an illness or after hospitalization and includes skilled nursing and physical, occupational and speech therapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
